Lotus Clinical Research congratulates Avenue Therapeutics’ “on their positive topline data from a second pivotal phase 3 study of intravenous Tramadol in the management of postoperative pain.” Lotus Clinical Research partnered with Avenue as the CRO on this program and served as one of the analgesic research sites used in the study. Avenue’s product, IV Tramadol, provides an important post-surgery alternative to pain management.  To read the full Avenue Therapeutics press release, click here for more information.